Table 3:
Percent survival across recent trials for people with newly diagnosed glioblastoma at two and three years for all patients and patients with MGMT promoter methylation.
| 2 year survival All patients (%, 95% CI) |
3 year survival All patients (%, 95% CI) |
2 year survival MGMT methylated (%, 95% CI) |
3 year survival MGMT methylated (%, 95% CI) |
|
|---|---|---|---|---|
| EORTC/NCIC (3) | N = 287 27 (22 – 33) |
N = 287 16 (12 – 20) |
N = 46 49 (34 – 62) |
N = 46 28 (15 – 41) |
| RTOG 0525 (4) | N = 411 34 |
N = 122 estimated 45 |
||
| NABTT RT and TMZ + new agent (5) |
N = 143 37 (29 – 46) |
|||
| CENTRIC EORTC 26071–22072 (16) | N = 272 56 (49–61) |
|||
| ABTC (Iniparib), present study | N = 81 38 (28 – 50) |
N = 81 25 (16 – 36) |
N = 29 59 (39 – 77) |
N = 29 38 (21 – 58) |